ME02179B - Metoda za lečenje atrijalne fibrilacije - Google Patents
Metoda za lečenje atrijalne fibrilacijeInfo
- Publication number
- ME02179B ME02179B MEP-2015-113A MEP11315A ME02179B ME 02179 B ME02179 B ME 02179B ME P11315 A MEP11315 A ME P11315A ME 02179 B ME02179 B ME 02179B
- Authority
- ME
- Montenegro
- Prior art keywords
- ranolazine
- dronedarone
- salt
- per day
- formulation
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 3
- 206010003658 Atrial Fibrillation Diseases 0.000 title claims 2
- XKLMZUWKNUAPSZ-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 XKLMZUWKNUAPSZ-UHFFFAOYSA-N 0.000 claims 17
- 229960000213 ranolazine Drugs 0.000 claims 17
- ZQTNQVWKHCQYLQ-UHFFFAOYSA-N dronedarone Chemical compound C1=CC(OCCCN(CCCC)CCCC)=CC=C1C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12 ZQTNQVWKHCQYLQ-UHFFFAOYSA-N 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 11
- 229960002084 dronedarone Drugs 0.000 claims 10
- 238000009472 formulation Methods 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 239000002775 capsule Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- CPKOXUVSOOKUDA-UHFFFAOYSA-N 1-bromo-5-fluoro-2-iodo-4-methylbenzene Chemical group CC1=CC(I)=C(Br)C=C1F CPKOXUVSOOKUDA-UHFFFAOYSA-N 0.000 claims 2
- 229960002919 dronedarone hydrochloride Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000013268 sustained release Methods 0.000 claims 2
- 239000012730 sustained-release form Substances 0.000 claims 2
- 206010003662 Atrial flutter Diseases 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Epoxy Compounds (AREA)
Claims (17)
1.Ranolazin za primenu u metodi za lečenje ili prevenciju atrijalne fibrilacije ili atrijalnog flatera kod humanog pacijenta kod koga postoji takva potreba, pri čemu metod obuhvata administraciju pacijentu terapijski efikasne količine dronedarona ili njegove farmaceutski prihvatUive soli i terapijski efikasne količine ranolazina.
2.Ranolazin za primenu prema patentnom zahtevu l , gde su dronedaron ili nJegova so ranolazin administrirani odvojeno ili zajedno kao kombinovana dozna jedinica, gde je poželjno daje kombinovana dozna jedinica, tableta.
3.Ranolazin za pnmenu prema patentnom zahtevu l , gde su dronedaron ili nJegova so ranolazin administrirani intravenski ili oralno.
4.Ranolazin za primenu prema bilo kom od patentnih zahteva 1-3, gde je količina ranolazina koja je administrirana od oko 50 mg do oko 3000 mg dnevno, poželjno od oko 50 mg do oko 1500 mg dnevno.
5.Ranolazin za primenu prema bilo kom od patentnih zahteva 1-4, gde je količina dronedarona ili njegove soli koja je administrirana od oko 50 mg do oko 800 mg dnevno, poželjno od oko 50 mg do oko 600 mg dnevno i još poželjnije od oko 50 mg do oko 400 mg dnevno.
6.Ranolazin za primenu prema bilo kom od patentnih zahteva 1-5, gde je količina dronedarona ili njegove soli koja je administrirana od oko 50 mg do oko 300 mg dnevno, a količina ranolazina koja je administrirana od oko 300 mg do oko 1000 mg dnevno.
7.Ranolazin za primenu prema patentnom zahtevu 6, gde je količina dronedarona ili njegove soli koja je administrirana od oko 50 mg do oko 200 mg dnevno.
8.Ranolazin za primenu prema bilo kom od patentnih zahteva 1-7, gde je so dronedarona, dronedaron hidrohlorid.
9. Farmaceutska formulacija koja sadrži ranolazin prihvatljivu so, i farmaceutski prihvatljivi nosač. dronedaron ili njegovu farmaceutski prihvatljivu so, i farmaceutski prihvatljivi nosač.
10.Farmaceutska formulacija patentnog zahteva 9, koja Je fomulisana za intravensku administraciju ili oralnu aministraciju.
11.Farmaceutska formulacija patentnog zahteva 9, gde je formulacija u obliku tablete ili kapsule.
12.Formulacija patentnog zahteva ll , gde tableta ili kapsula sadrži od oko 25 mg do oko 600 mg, poželjno od oko 50 mg do oko 200 mg dronedarona ili njegove soli.
13. Formulacija patentnog zahteva ll ili 12, gde tableta ili kapsula sadrži od oko 50 mg do oko 1000 mg, poželjno od oko 100 mg do oko 750 mg ranolazina.
14.Formulacija patentnog zahteva ll, gde tableta ili kapsula sadrži od oko l OO mg do oko 750 mg ranolazina i oko 50 mg do oko 200 mg dronedarona ili njegove soli.
15.Formulacija prema bilo kom od patentnih zahteva 9-14, gde je so dronedarona, dronedaron hidrohlorid.
16.Formulacija prema bilo kom od patentnih zahteva 9-15, gde je ranolazin formulisan za produženo oslobađanje.
17. Formulacija prema bilo kom od patentnih zahteva 9-15, gde je dronedaron ili njegova so formulisan za momentalno oslobađanje ili produženo oslobađanje.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28873909P | 2009-12-21 | 2009-12-21 | |
| EP20100798436 EP2515900B1 (en) | 2009-12-21 | 2010-12-20 | Method of treating atrial fibrillation |
| PCT/US2010/061257 WO2011084733A1 (en) | 2009-12-21 | 2010-12-20 | Method of treating atrial fibrillation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02179B true ME02179B (me) | 2015-10-20 |
Family
ID=43736345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-113A ME02179B (me) | 2009-12-21 | 2010-12-20 | Metoda za lečenje atrijalne fibrilacije |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US8513254B2 (me) |
| EP (2) | EP2749282B1 (me) |
| JP (2) | JP5723889B2 (me) |
| KR (2) | KR20160108611A (me) |
| CN (3) | CN102665713B (me) |
| AP (1) | AP3536A (me) |
| AR (1) | AR079552A1 (me) |
| AU (1) | AU2010339753B2 (me) |
| BR (1) | BR112012015499A2 (me) |
| CA (1) | CA2784028C (me) |
| CL (1) | CL2012001597A1 (me) |
| CR (1) | CR20120353A (me) |
| CY (1) | CY1116511T1 (me) |
| DK (1) | DK2515900T3 (me) |
| EA (2) | EA201691336A1 (me) |
| EC (1) | ECSP12012004A (me) |
| ES (2) | ES2540093T3 (me) |
| HR (1) | HRP20150644T1 (me) |
| HU (1) | HUE026916T2 (me) |
| IL (1) | IL220152A (me) |
| ME (1) | ME02179B (me) |
| MX (2) | MX2012007052A (me) |
| NO (1) | NO2749282T3 (me) |
| NZ (2) | NZ600718A (me) |
| PE (1) | PE20121520A1 (me) |
| PL (2) | PL2515900T3 (me) |
| PT (2) | PT2515900E (me) |
| RS (1) | RS54118B1 (me) |
| SG (3) | SG181541A1 (me) |
| SI (2) | SI2749282T1 (me) |
| SM (1) | SMT201500171B (me) |
| TW (1) | TWI508726B (me) |
| UA (1) | UA109887C2 (me) |
| UY (1) | UY33119A (me) |
| WO (1) | WO2011084733A1 (me) |
| ZA (1) | ZA201204608B (me) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2486712C (en) | 2002-05-21 | 2012-01-03 | Cv Therapeutics, Inc. | Method of treating diabetes |
| ME02847B (me) | 2009-07-27 | 2018-01-20 | Gilead Sciences Inc | Fuzionisana heterociklična jedinjenja kao modulatori jonskih kanala |
| CN104873389B (zh) | 2009-07-29 | 2017-12-05 | Icu医学有限公司 | 流体传输装置及使用方法 |
| WO2011135582A2 (en) * | 2010-04-28 | 2011-11-03 | Cadila Healthcare Limited | Pharmaceutical compositions of dronedarone |
| BR112012033402A2 (pt) | 2010-07-02 | 2017-01-24 | Gilead Sciences Inc | moduladores de canais de íons conforme os compostos heterocíclicos fundidos |
| ES2648820T3 (es) | 2011-05-10 | 2018-01-08 | Gilead Sciences, Inc. | Compuestos heterocíclicos condensados como moduladores de los canales de sodio |
| NO3175985T3 (me) | 2011-07-01 | 2018-04-28 | ||
| TWI478908B (zh) | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | 作為離子通道調節劑之稠合雜環化合物 |
| WO2013112932A1 (en) * | 2012-01-27 | 2013-08-01 | Gilead Sciences, Inc. | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
| US20140364417A1 (en) * | 2013-05-03 | 2014-12-11 | Gilead Sciences, Inc. | Method of treating atrial fibrillation |
| KR20160027078A (ko) * | 2013-08-02 | 2016-03-09 | 길리애드 사이언시즈, 인코포레이티드 | 라놀라진 및 드로네다론의 제약 조성물 |
| WO2015073922A2 (en) | 2013-11-15 | 2015-05-21 | Northwestern University | Inhibition of oxidative stress in atrial fibrillation |
| EP3083608B1 (en) | 2013-12-19 | 2018-07-18 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| CN104951870B (zh) * | 2015-06-01 | 2018-11-13 | 南通科瑞斯生物医药科技有限公司 | 药物临床前心脏风险评估方法 |
| US20190119236A1 (en) | 2016-02-23 | 2019-04-25 | Portola Pharmaceuticals, Inc. | Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9) |
| CA3016081A1 (en) | 2016-03-04 | 2017-09-08 | Gilead Sciences, Inc. | Compositions and combinations of autotaxin inhibitors |
| US10575744B2 (en) | 2017-02-24 | 2020-03-03 | Medtronic Cryocath Lp | Pericardial balloon mapping |
| US10799703B2 (en) * | 2017-12-22 | 2020-10-13 | Medtronic, Inc. | Evaluation of his bundle pacing therapy |
| EP3530182B1 (en) * | 2018-02-27 | 2020-12-09 | Nokia Technologies Oy | Apparatus and method for determining a change in left ventricular twist of a subject's heart |
| CA3103522C (en) * | 2018-07-16 | 2023-11-21 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of hiv |
| EP3914709A4 (en) * | 2019-01-24 | 2023-05-03 | Northwestern University | Gene therapy treatment of atrial fibrillation |
| US11712188B2 (en) * | 2019-05-07 | 2023-08-01 | Medtronic, Inc. | Posterior left bundle branch engagement |
| IL290088B2 (en) | 2019-08-01 | 2023-10-01 | Incarda Therapeutics Inc | A pharmaceutical preparation containing flacainide, cyclodextrin and acid, a dosage unit of the preparation and a kit containing the preparation |
| PL4445900T3 (pl) | 2021-12-03 | 2025-09-22 | Gilead Sciences, Inc. | Związki terapeutyczne przeciwko zakażeniu wirusem hiv |
| KR20240113832A (ko) | 2021-12-03 | 2024-07-23 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 바이러스 감염 치료용 화합물 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4567264A (en) | 1983-05-18 | 1986-01-28 | Syntex (U.S.A.) Inc. | Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| ATE218344T1 (de) | 1989-06-23 | 2002-06-15 | Syntex Llc | Ranolazin und verwandte piperazine zur behandlung von schockzuständen |
| FR2665444B1 (fr) | 1990-08-06 | 1992-11-27 | Sanofi Sa | Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant. |
| US5455045A (en) | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
| ZA953078B (en) * | 1994-04-28 | 1996-01-05 | Alza Corp | Effective therapy for epilepsies |
| FR2764800B1 (fr) | 1997-06-23 | 1999-09-10 | Sanofi Sa | Composition pharmaceutique solide contenant des derives de benzofuranne |
| US6303607B1 (en) | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
| US20020042405A1 (en) * | 2000-07-27 | 2002-04-11 | Schuh Joseph R. | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure |
| FR2817750B1 (fr) | 2000-12-11 | 2003-02-21 | Sanofi Synthelabo | Composition pharmaceutique de dronedarone pour administration parenterale |
| EP1347756B1 (en) | 2000-12-27 | 2006-03-08 | Genzyme Corporation | Controlled release of anti-arrhythmic agents from a biodegradable hydrogel for local application to the heart |
| WO2003009839A1 (en) * | 2001-07-20 | 2003-02-06 | Karo Bio Ab | Benzofuranes and their use in the treatment of atrial fibrillation |
| US20060003002A1 (en) * | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
| US7772232B2 (en) | 2004-04-15 | 2010-08-10 | Bristol-Myers Squibb Company | Quinazolinyl compounds as inhibitors of potassium channel function |
| WO2006074398A2 (en) | 2005-01-06 | 2006-07-13 | Cv Therapeutics, Inc. | Sustained release pharmaceutical formulations comprising ranolazine |
| WO2007053610A2 (en) | 2005-11-01 | 2007-05-10 | The Regents Of The University Of California | Methods of treating atrial fibrillation wtih pirfenidone |
| EP2117508A1 (en) * | 2007-02-13 | 2009-11-18 | CV Therapeutics Inc. | Intravenous solutions comprising ranolazine |
| US20090247535A1 (en) * | 2008-03-26 | 2009-10-01 | Duke University | Use of ranolazine for non-cardiovascular disorders |
| EP2133074A1 (en) * | 2008-06-10 | 2009-12-16 | Sanofi-Aventis | Use of dronedarone for the preparation of a medicament intended for the prevention of permanent atrial fibrillation |
| US20100056536A1 (en) | 2008-09-04 | 2010-03-04 | Charles Antzelevitch | Method of treating atrial fibrillation |
-
2010
- 2010-12-16 TW TW099144230A patent/TWI508726B/zh not_active IP Right Cessation
- 2010-12-20 DK DK10798436.1T patent/DK2515900T3/en active
- 2010-12-20 ME MEP-2015-113A patent/ME02179B/me unknown
- 2010-12-20 EA EA201691336A patent/EA201691336A1/ru unknown
- 2010-12-20 SG SG2012041638A patent/SG181541A1/en unknown
- 2010-12-20 KR KR1020167024642A patent/KR20160108611A/ko not_active Ceased
- 2010-12-20 JP JP2012544937A patent/JP5723889B2/ja active Active
- 2010-12-20 ES ES10798436.1T patent/ES2540093T3/es active Active
- 2010-12-20 HU HUE10798436A patent/HUE026916T2/en unknown
- 2010-12-20 AP AP2012006331A patent/AP3536A/xx active
- 2010-12-20 EP EP14161300.0A patent/EP2749282B1/en active Active
- 2010-12-20 US US12/972,949 patent/US8513254B2/en not_active Expired - Fee Related
- 2010-12-20 BR BR112012015499A patent/BR112012015499A2/pt not_active IP Right Cessation
- 2010-12-20 EP EP20100798436 patent/EP2515900B1/en active Active
- 2010-12-20 UA UAA201208208A patent/UA109887C2/uk unknown
- 2010-12-20 CN CN201080058336.3A patent/CN102665713B/zh not_active Expired - Fee Related
- 2010-12-20 EA EA201290451A patent/EA025445B1/ru not_active IP Right Cessation
- 2010-12-20 ES ES14161300.0T patent/ES2646603T3/es active Active
- 2010-12-20 UY UY33119A patent/UY33119A/xx not_active Application Discontinuation
- 2010-12-20 AR ARP100104774A patent/AR079552A1/es unknown
- 2010-12-20 SI SI201031571T patent/SI2749282T1/sl unknown
- 2010-12-20 MX MX2012007052A patent/MX2012007052A/es active IP Right Grant
- 2010-12-20 NO NO14161300A patent/NO2749282T3/no unknown
- 2010-12-20 CA CA2784028A patent/CA2784028C/en not_active Expired - Fee Related
- 2010-12-20 SI SI201030949T patent/SI2515900T1/sl unknown
- 2010-12-20 MX MX2014002642A patent/MX344329B/es unknown
- 2010-12-20 KR KR1020127018477A patent/KR20120107995A/ko not_active Ceased
- 2010-12-20 SG SG10201408528RA patent/SG10201408528RA/en unknown
- 2010-12-20 NZ NZ600718A patent/NZ600718A/en not_active IP Right Cessation
- 2010-12-20 RS RS20150489A patent/RS54118B1/sr unknown
- 2010-12-20 NZ NZ627181A patent/NZ627181A/en not_active IP Right Cessation
- 2010-12-20 HR HRP20150644TT patent/HRP20150644T1/hr unknown
- 2010-12-20 CN CN201410377525.7A patent/CN104147010A/zh active Pending
- 2010-12-20 SG SG10201710751TA patent/SG10201710751TA/en unknown
- 2010-12-20 CN CN201510028705.9A patent/CN104688739A/zh active Pending
- 2010-12-20 PL PL10798436T patent/PL2515900T3/pl unknown
- 2010-12-20 PE PE2012000852A patent/PE20121520A1/es active IP Right Grant
- 2010-12-20 AU AU2010339753A patent/AU2010339753B2/en not_active Ceased
- 2010-12-20 PT PT107984361T patent/PT2515900E/pt unknown
- 2010-12-20 PL PL14161300T patent/PL2749282T3/pl unknown
- 2010-12-20 WO PCT/US2010/061257 patent/WO2011084733A1/en not_active Ceased
- 2010-12-20 PT PT141613000T patent/PT2749282T/pt unknown
-
2012
- 2012-06-04 IL IL220152A patent/IL220152A/en not_active IP Right Cessation
- 2012-06-14 CL CL2012001597A patent/CL2012001597A1/es unknown
- 2012-06-21 ZA ZA2012/04608A patent/ZA201204608B/en unknown
- 2012-06-27 EC ECSP12012004 patent/ECSP12012004A/es unknown
- 2012-06-27 CR CR20120353A patent/CR20120353A/es not_active Application Discontinuation
-
2013
- 2013-05-31 US US13/907,349 patent/US8754087B2/en not_active Expired - Fee Related
-
2014
- 2014-03-20 US US14/221,014 patent/US9056108B2/en not_active Expired - Fee Related
- 2014-12-22 JP JP2014258433A patent/JP2015057449A/ja not_active Withdrawn
-
2015
- 2015-07-14 SM SM201500171T patent/SMT201500171B/xx unknown
- 2015-07-17 CY CY20151100625T patent/CY1116511T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02179B (me) | Metoda za lečenje atrijalne fibrilacije | |
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| FI3936130T3 (fi) | Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon | |
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| EA200900264A1 (ru) | Композиции флибансерина и способ их приготовления | |
| FI3782612T3 (fi) | Sytidiinianalogien oraalisia formulaatioita ja menetelmiä niiden käyttämiseksi | |
| JP2015038135A5 (me) | ||
| JP2015522630A5 (me) | ||
| JP2007532663A5 (me) | ||
| FI3435996T3 (fi) | Elafibranori käytettäväksi primaarisen biliaarisen kolangiitin hoidossa | |
| JP2015524444A5 (me) | ||
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| HRP20250266T1 (hr) | Nukleotid hemi-sulfat sol za liječenje virusa hepatitisa c | |
| UA116334C2 (uk) | Тверді форми дозування бендамустину | |
| JP2015523407A5 (me) | ||
| ME02474B (me) | Terapijski režimi | |
| JP2015519329A5 (me) | ||
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| JP2012502047A5 (me) | ||
| WO2008142572A3 (en) | Controlled release tablet formulation containing magnesium aluminometasilicate | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| JP2015510916A5 (me) | ||
| JP2013541583A5 (me) | ||
| JP2013518914A5 (me) |